Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs
• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Datta, Jharna [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:56 ; year:2016 ; pages:32-39 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2016.02.015 |
|---|
| Katalog-ID: |
ELV029476305 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029476305 | ||
| 003 | DE-627 | ||
| 005 | 20230623201347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2016.02.015 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016002000024.pica |
| 035 | |a (DE-627)ELV029476305 | ||
| 035 | |a (ELSEVIER)S1368-8375(16)00045-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Datta, Jharna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| 264 | 1 | |c 2016 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. | ||
| 650 | 7 | |a miR-138 |2 Elsevier | |
| 650 | 7 | |a HDAC inhibitor |2 Elsevier | |
| 650 | 7 | |a PKCε |2 Elsevier | |
| 650 | 7 | |a Head and neck cancer |2 Elsevier | |
| 650 | 7 | |a RhoC |2 Elsevier | |
| 650 | 7 | |a Tumor suppressor miR |2 Elsevier | |
| 650 | 7 | |a miR-107 |2 Elsevier | |
| 650 | 7 | |a Suberoylanilide hydroxamic acid |2 Elsevier | |
| 700 | 1 | |a Islam, Mozaffarul |4 oth | |
| 700 | 1 | |a Dutta, Samidha |4 oth | |
| 700 | 1 | |a Roy, Sounak |4 oth | |
| 700 | 1 | |a Pan, Quintin |4 oth | |
| 700 | 1 | |a Teknos, Theodoros N. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:56 |g year:2016 |g pages:32-39 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2016.02.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 56 |j 2016 |h 32-39 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j d jd |
|---|---|
| matchkey_str |
dattajharnaislammozaffarulduttasamidharo:2016----:ueolnldhdoaiaiihbtgotohaadekacreliebratv |
| hierarchy_sort_str |
2016 |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2016 |
| allfields |
10.1016/j.oraloncology.2016.02.015 doi GBVA2016002000024.pica (DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Datta, Jharna verfasserin aut Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier Islam, Mozaffarul oth Dutta, Samidha oth Roy, Sounak oth Pan, Quintin oth Teknos, Theodoros N. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:56 year:2016 pages:32-39 extent:8 https://doi.org/10.1016/j.oraloncology.2016.02.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 56 2016 32-39 8 045F 610 |
| spelling |
10.1016/j.oraloncology.2016.02.015 doi GBVA2016002000024.pica (DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Datta, Jharna verfasserin aut Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier Islam, Mozaffarul oth Dutta, Samidha oth Roy, Sounak oth Pan, Quintin oth Teknos, Theodoros N. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:56 year:2016 pages:32-39 extent:8 https://doi.org/10.1016/j.oraloncology.2016.02.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 56 2016 32-39 8 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2016.02.015 doi GBVA2016002000024.pica (DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Datta, Jharna verfasserin aut Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier Islam, Mozaffarul oth Dutta, Samidha oth Roy, Sounak oth Pan, Quintin oth Teknos, Theodoros N. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:56 year:2016 pages:32-39 extent:8 https://doi.org/10.1016/j.oraloncology.2016.02.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 56 2016 32-39 8 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2016.02.015 doi GBVA2016002000024.pica (DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Datta, Jharna verfasserin aut Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier Islam, Mozaffarul oth Dutta, Samidha oth Roy, Sounak oth Pan, Quintin oth Teknos, Theodoros N. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:56 year:2016 pages:32-39 extent:8 https://doi.org/10.1016/j.oraloncology.2016.02.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 56 2016 32-39 8 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2016.02.015 doi GBVA2016002000024.pica (DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Datta, Jharna verfasserin aut Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier Islam, Mozaffarul oth Dutta, Samidha oth Roy, Sounak oth Pan, Quintin oth Teknos, Theodoros N. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:56 year:2016 pages:32-39 extent:8 https://doi.org/10.1016/j.oraloncology.2016.02.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 56 2016 32-39 8 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:56 year:2016 pages:32-39 extent:8 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:56 year:2016 pages:32-39 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
miR-138 HDAC inhibitor PKCε Head and neck cancer RhoC Tumor suppressor miR miR-107 Suberoylanilide hydroxamic acid |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Datta, Jharna @@aut@@ Islam, Mozaffarul @@oth@@ Dutta, Samidha @@oth@@ Roy, Sounak @@oth@@ Pan, Quintin @@oth@@ Teknos, Theodoros N. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV029476305 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029476305</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201347.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2016.02.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029476305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(16)00045-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Datta, Jharna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miR-138</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HDAC inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PKCε</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RhoC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumor suppressor miR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miR-107</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Suberoylanilide hydroxamic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Islam, Mozaffarul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dutta, Samidha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Sounak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Quintin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teknos, Theodoros N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:32-39</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2016.02.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2016</subfield><subfield code="h">32-39</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Datta, Jharna |
| spellingShingle |
Datta, Jharna ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| authorStr |
Datta, Jharna |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier miR-138 Elsevier HDAC inhibitor Elsevier PKCε Elsevier Head and neck cancer Elsevier RhoC Elsevier Tumor suppressor miR Elsevier miR-107 Elsevier Suberoylanilide hydroxamic acid |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m i mi s d sd s r sr q p qp t n t tn tnt |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| ctrlnum |
(DE-627)ELV029476305 (ELSEVIER)S1368-8375(16)00045-2 |
| title_full |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| author_sort |
Datta, Jharna |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
32 |
| author_browse |
Datta, Jharna |
| container_volume |
56 |
| physical |
8 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Datta, Jharna |
| doi_str_mv |
10.1016/j.oraloncology.2016.02.015 |
| dewey-full |
610 650 |
| title_sort |
suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor micrornas |
| title_auth |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| abstract |
• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. |
| abstractGer |
• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. |
| abstract_unstemmed |
• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| url |
https://doi.org/10.1016/j.oraloncology.2016.02.015 |
| remote_bool |
true |
| author2 |
Islam, Mozaffarul Dutta, Samidha Roy, Sounak Pan, Quintin Teknos, Theodoros N. |
| author2Str |
Islam, Mozaffarul Dutta, Samidha Roy, Sounak Pan, Quintin Teknos, Theodoros N. |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2016.02.015 |
| up_date |
2024-07-06T21:34:02.293Z |
| _version_ |
1803867014871121920 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029476305</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201347.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2016.02.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029476305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(16)00045-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Datta, Jharna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• SAHA treatment results in reactivation of the silenced tumor suppressor miRs. • SAHA treatment reduced expression of PKCε, HIF1β, CDK6, and RhoC oncoproteins. • Combination treatment with SAHA and cisplatin reduced cell growth significantly. • SAHA treatment enhances the efficacy of standard chemo-/radiation therapy in HNSCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miR-138</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HDAC inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PKCε</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RhoC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumor suppressor miR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">miR-107</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Suberoylanilide hydroxamic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Islam, Mozaffarul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dutta, Samidha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Sounak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Quintin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teknos, Theodoros N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:32-39</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2016.02.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2016</subfield><subfield code="h">32-39</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4004145 |